DHR Q3 2025 Report HIGHLIGHTS EPS: $1.89, approximately 10% above the consensus estimate of $1.72
Biotechnology Segment: Grew 8.8% year-on-year, continuing its streak of quarterly growth
Financials: Free cash flow for the quarter was $1.4 billion, with the operating profit margin increasing 40 basis points year-on-year to 27.9%
Share Repurchase: The company repurchased 10 million shares for $2.01 billion. In September 2025, a new share repurchase program of up to 35 million shares was approved by the Board
2026 Guidance: Management provided its first guidance for 2026, expecting core revenue growth in the range of 3-6% and EPS growth.
KEY DRIVERS
🔎
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.